AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
pasireotide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| peptides and glycopeptides | 4329 | 396091-73-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a somatostatin analog with pharmacologic properties mimicking those of the natural hormone somatostatin binds and activates the SSTRs resulting in inhibition of ACTH secretion, which leads to decreased cortisol secretion
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.20 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| S (Water solubility) | 100 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK5,EGFR,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MET,NTRK2,PDK1,PDK2,PDK4,PRKDC | 17 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 14, 2012 | FDA | NOVARTIS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperglycaemia | 434.94 | 33.10 | 126 | 2579 | 50844 | 90574898 |
| Diabetes mellitus | 400.72 | 33.10 | 125 | 2580 | 64750 | 90560992 |
| Glycosylated haemoglobin increased | 91.51 | 33.10 | 29 | 2676 | 15533 | 90610209 |
| Blood glucose increased | 90.89 | 33.10 | 48 | 2657 | 95198 | 90530544 |
| Hypoglycaemia | 74.64 | 33.10 | 38 | 2667 | 69810 | 90555932 |
| Cholelithiasis | 69.31 | 33.10 | 33 | 2672 | 52473 | 90573269 |
| Adrenal insufficiency | 62.66 | 33.10 | 26 | 2679 | 29895 | 90595847 |
| Cortisol free urine increased | 50.68 | 33.10 | 7 | 2698 | 55 | 90625687 |
| Insulinoma | 44.83 | 33.10 | 7 | 2698 | 136 | 90625606 |
| Polyuria | 44.04 | 33.10 | 15 | 2690 | 10025 | 90615717 |
| Insulin-like growth factor decreased | 43.85 | 33.10 | 8 | 2697 | 404 | 90625338 |
| Nocturia | 43.73 | 33.10 | 15 | 2690 | 10240 | 90615502 |
| Insulin-like growth factor increased | 42.66 | 33.10 | 9 | 2696 | 965 | 90624777 |
| Diabetes mellitus inadequate control | 41.70 | 33.10 | 17 | 2688 | 18667 | 90607075 |
| Urine calcium/creatinine ratio increased | 38.40 | 33.10 | 6 | 2699 | 117 | 90625625 |
| Polydipsia | 38.29 | 33.10 | 11 | 2694 | 4220 | 90621522 |
| Bite | 35.75 | 33.10 | 7 | 2698 | 517 | 90625225 |
| Glucocorticoid deficiency | 35.10 | 33.10 | 7 | 2698 | 568 | 90625174 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperglycaemia | 166.38 | 36.82 | 55 | 902 | 45804 | 42574574 |
| Diabetes mellitus | 125.95 | 36.82 | 48 | 909 | 60039 | 42560339 |
| Hyperadrenocorticism | 44.71 | 36.82 | 7 | 950 | 187 | 42620191 |
| Polyuria | 40.06 | 36.82 | 13 | 944 | 9998 | 42610380 |
| Neoplasm progression | 39.25 | 36.82 | 17 | 940 | 28983 | 42591395 |
| Diabetes mellitus inadequate control | 38.27 | 36.82 | 14 | 943 | 15376 | 42605002 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperglycaemia | 471.86 | 33.26 | 152 | 3238 | 84938 | 110500971 |
| Diabetes mellitus | 444.73 | 33.26 | 151 | 3239 | 99230 | 110486679 |
| Glycosylated haemoglobin increased | 97.76 | 33.26 | 34 | 3356 | 23585 | 110562324 |
| Hypoglycaemia | 88.67 | 33.26 | 51 | 3339 | 116053 | 110469856 |
| Adrenal insufficiency | 88.40 | 33.26 | 37 | 3353 | 42353 | 110543556 |
| Cholelithiasis | 83.12 | 33.26 | 40 | 3350 | 63382 | 110522527 |
| Diabetes mellitus inadequate control | 79.33 | 33.26 | 31 | 3359 | 29744 | 110556165 |
| Blood glucose increased | 77.38 | 33.26 | 49 | 3341 | 132447 | 110453462 |
| Polyuria | 75.19 | 33.26 | 26 | 3364 | 17712 | 110568197 |
| Hyperadrenocorticism | 65.75 | 33.26 | 12 | 3378 | 591 | 110585318 |
| Cortisol increased | 58.76 | 33.26 | 11 | 3379 | 623 | 110585286 |
| Cortisol free urine increased | 57.80 | 33.26 | 8 | 3382 | 62 | 110585847 |
| Polydipsia | 51.76 | 33.26 | 16 | 3374 | 7672 | 110578237 |
| Glucocorticoid deficiency | 46.26 | 33.26 | 10 | 3380 | 1172 | 110584737 |
| Insulinoma | 42.16 | 33.26 | 7 | 3383 | 197 | 110585712 |
| Insulin-like growth factor decreased | 40.46 | 33.26 | 8 | 3382 | 605 | 110585304 |
| Neoplasm progression | 40.45 | 33.26 | 25 | 3365 | 64570 | 110521339 |
| Urine calcium/creatinine ratio increased | 36.86 | 33.26 | 6 | 3384 | 149 | 110585760 |
| Insulin-like growth factor increased | 34.74 | 33.26 | 9 | 3381 | 2287 | 110583622 |
| Bite | 34.33 | 33.26 | 7 | 3383 | 618 | 110585291 |
| Urethral caruncle | 33.36 | 33.26 | 5 | 3385 | 71 | 110585838 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | H01CB05 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES HYPOTHALAMIC HORMONES Somatostatin and analogues |
| FDA MoA | N0000000194 | Somatostatin Receptor Agonists |
| MeSH PA | D006728 | Hormones |
| FDA EPC | N0000175904 | Somatostatin Analog |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:76916 | hyperglycemic agent |
Related Drugs by ATC class:
H01CB Somatostatin and analogues 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypercortisolism | indication | 47270006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.8 | acidic |
| pKa2 | 13.26 | acidic |
| pKa3 | 13.4 | acidic |
| pKa4 | 13.93 | acidic |
| pKa5 | 10.31 | Basic |
| pKa6 | 8.91 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Somatostatin receptor type 2 | GPCR | AGONIST | IC50 | 9 | IUPHAR | CHEMBL | |||
| Somatostatin receptor type 3 | GPCR | AGONIST | IC50 | 8.80 | IUPHAR | CHEMBL | |||
| Somatostatin receptor type 5 | GPCR | AGONIST | IC50 | 9.80 | IUPHAR | CHEMBL | |||
| Somatostatin receptor type 1 | GPCR | AGONIST | IC50 | 8 | IUPHAR | CHEMBL | |||
| Somatostatin receptor type 2 | GPCR | AGONIST | EC50 | 9.07 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4032239 | VUID |
| N0000186784 | NUI |
| D10147 | KEGG_DRUG |
| 4032239 | VANDF |
| C1872203 | UMLSCUI |
| CHEBI:72312 | CHEBI |
| CHEMBL3349607 | ChEMBL_ID |
| CHEMBL5314380 | ChEMBL_ID |
| DB06663 | DRUGBANK_ID |
| C517782 | MESH_SUPPLEMENTAL_RECORD_UI |
| 2018 | IUPHAR_LIGAND_ID |
| 8384 | INN_ID |
| 820232-50-6 | SECONDARY_CAS_RN |
| 98H1T17066 | UNII |
| 9941444 | PUBCHEM_CID |
| 1364104 | RXNORM |
| 192917 | MMSL |
| 28816 | MMSL |
| 29021 | MMSL |
| 30767 | MMSL |
| d07903 | MMSL |
| 014802 | NDDF |
| 014803 | NDDF |
| 015818 | NDDF |
| 704266003 | SNOMEDCT_US |
| 704267007 | SNOMEDCT_US |
| 704269005 | SNOMEDCT_US |
| 734521009 | SNOMEDCT_US |
| CHEMBL5314382 | ChEMBL_ID |
| 396091-79-5 | SECONDARY_CAS_RN |
| 98H1T17066 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Signifor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55292-131 | INJECTION | 0.30 mg | SUBCUTANEOUS | NDA | 31 sections |
| Signifor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55292-132 | INJECTION | 0.60 mg | SUBCUTANEOUS | NDA | 31 sections |
| Signifor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55292-133 | INJECTION | 0.90 mg | SUBCUTANEOUS | NDA | 31 sections |